ArticleOncoTargets and therapy2018

Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study.

Minjun Dong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.